Navigation Links
Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
Date:11/2/2007

LOS ANGELES, Nov. 2 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP). "We believe Raptor's operational approach will serve as the template for all small cap biotechnology companies as it promotes operational efficiency, reduced operating costs and efficient allocation of human resources. Also, Raptor now has a Phase II candidate for 2008 in Convivia(TM), which will treat a large patient population in a billion dollar plus market," stated Ross Silver, Director of Research for Vista Partners. Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report for free, please visit the Vista Partners website at http://www.vistap.com.

Raptor's CEO, Dr. Christopher M. Starr, is presenting at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at The New York Palace Hotel on Monday, November 5, 2007 at 4:05 p.m. ET. A webcast of Dr. Starr's presentation, including slides, will be posted on Raptor's website, live and archived for 90 days.

About Raptor:

Raptor Pharmaceuticals Corp.'s business consists of two segments: its 100% ownership of Raptor Pharmaceutical Inc. ("Raptor Inc."), a development stage biotechnology company which bioengineers novel drug candidates and drug- targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins; and its 100% ownership of Bennu Pharmaceuticals Inc., a development stage company formed to develop clinical-stage products to marketing approval and commercialization. Raptor Inc.'s preclinical programs target cancer, neurodegenerative disorders, infectious diseases and osteoporosis. HepTide(TM) is designed to utilize engineered RAP-based peptides conjugated to drugs to target their delivery to the liver. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In an effort to protect its novel approach, Raptor Inc. currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, Raptor Inc. has recently submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, with the second application to further support and expand its coverage in specific disease indications.

Bennu's initial clinical program includes the treatment of aldehyde dehydrogenase ("ALDH2") deficiency. For additional information, please visit http://www.raptorpharma.com.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Evista Not A Cure For Heart Disease
2. Spouses and other partners lower blood pressure says new research
3. Changing Partners may put Expectant Mothers at Risk
4. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
5. Partnership Between Diabetes India And Elsevier Announced
6. Betterment Of Health In Case Of Gay And Lesbian Civil Partnerships
7. Private Public Partnership To Tackle TB, In Karnataka
8. Courting HIV through Marriage or Partnership
9. Jealousy In Men Peaks When Partners Are Most Fertile
10. War Trauma Not Passed On To Partners And Children, Study
11. SRM Inst Signs Mou With Partners Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
Breaking Medicine Technology: